FIRM PROFILE Kirkland & Ellis LLP is a leading global law firm renowned for its dominance in private equity, M&A, restructuring, litigation, intellectual property, and executive compensation. Founded in 1909 and headquartered in Chicago, the firm has grown into a powerhouse with over 3,500 lawyers across 21 offices worldwide, including key locations in New York, London, Hong Kong, and Riyadh. Core Practice Areas Private Equity & M&A: Kirkland’s market-leading transactional teams advise on leveraged buyouts, complex corporate mergers, carve-outs, and crossborder deals, serving both sponsors and strategic acquirers. Restructuring & Insolvency: With over 200 dedicated attorneys in U.S., London, Munich, and Hong Kong, the firm is globally recognized— Ranked #1 in global restructuring for eight consecutive years. Litigation & Dispute Resolution: The firm operates a formidable trial-ready litigation department handling high-stakes commercial, IP, antitrust, and white-collar matters, with a top-tier success record. Intellectual Property: Kirkland offers deep bench strength in patent, trademark, trade-secret cases, and technology-driven disputes, leveraging crossdisciplinary transactional counsel as needed. Executive Compensation, Employment & Benefits: The team supports clients through M&A, spinoffs, restructurings, and IPOs— designing tailored compensation plans while navigating the evolving regulatory landscape. Kirkland & Ellis stands as a top-tier global firm— unmatched in transaction execution, litigation prowess, and legal innovation—powered by a globally integrated platform and a dynamic, client-focused culture. Spencer Klein is global M&A co-chair and head of the Corporate Department in New York. He has advised on more than 200 successfully closed mergers, tender and exchange offers, stock and asset acquisitions, divestitures, and joint ventures. He is considered the firm’s go-to partner on hostile M&A and shareholder activism defense. Spencer frequently advises leading U.S. and multinational companies across multiple industries. His engagements include multibillion-dollar deals in healthcare and life sciences, financial services, technology, consumer products, manufacturing, retail, energy, and entertainment and media. In addition to prominent corporate clients and private equity funds, he has represented some of the world’s leading bulge bracket and boutique investment banks. Notable recent matters include representing: • The rock band KISS and its co-founders Gene Simmons and Paul Stanley in the sale of substantially all rights related to KISS to Pophouse Entertainment. • U.S. Silica Holdings in its $1.85 billion sale to entities affiliated with Apollo Global Management. • Ascendent Capital Partners in its $1.66 billion acquisition of Hollysys. Kirkland & Ellis represented Edding Group Company Limited—a PRC-based integrated biopharmaceutical company focused on R&D and commercialization—in its proposed merger and reverse takeover of Genor Biopharma Holdings Limited, a Chapter 18A– listed oncology and immunology-focused biotech firm on the Hong Kong Stock Exchange. Announced in early October 2024, this transaction marks the first-ever Chapter 18A reverse takeover in Hong Kong and the only such deal publicly disclosed in the market at the time. The merger is designed to create compelling complementary capabilities between the two businesses: Edding brings deep commercialization know-how and a broad product portfolio in anti-infectives and respiratory therapies, complemented by Genor’s innovative oncology and immunology pipeline under Chapter 18A . The combination is expected to establish a more robust industrial model, fully integrating R&D, production, and sales, while offering Edding a backdoor listing into Hong Kong. The Kirkland team was led by capital markets partner Dr. Mengyu Lu, alongside corporate partners Joey Chau, Ashlee Wu, and Leo Zhou, and supported by associates Chuanwen Wang, Rock Liu, and registered foreign lawyer Sherry Fu. Kirkland & Ellis Advises Edding Group on Groundbreaking Reverse Takeover of Genor Biopharma www.kirkland.com Finance Monthly Deal Maker Awards 2025. CHINA 63
RkJQdWJsaXNoZXIy Mjk3Mzkz